Vivimed Labs Limited (VIVIMEDLAB)
₹6.45 -1.98% on 19 Oct, as of 12:25 IST · NSE
Latest quarterly results (Q4 FY26)
In its latest reported quarter, Q4 FY26, Vivimed Labs' revenue was ₹12.0 Cr, and net profit ₹-147 Cr; the operating margin was -1169.0%.
| Q4 FY26 (₹ Cr) | Value | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹12.0 | — | — |
| Operating profit | ₹-140 | — | — |
| Net profit | ₹-147 | — | — |
| EPS (₹) | -17.74 | — | — |
| Operating margin | -1169.0% | — | — |
VIVIMEDLAB exchange data
NSE end-of-day data for
It closed at its lower price band (circuit) on 16 Oct, one of 12 band closes in about the last 20 sessions.
A description of what the exchange published, not a recommendation. Names such as "accumulation" or "long buildup" label a pattern in the numbers. How delivery is analysed
📢 Recent Corporate Announcements
Vivimed Labs announced audited financial results for the year ended March 31, 2026, reporting a consolidated net loss of ₹1,764.73 million compared to a loss of ₹319.61 million in FY2025. Consolidated revenue from operations fell sharply to ₹695.61 million from ₹1,162.69 million in the prior year. Additionally, the company is under Corporate Insolvency Resolution Process (CIRP) admitted by the NCLT on April 15, 2026, leading to the suspension of the Board's powers and management handover to an Interim Resolution Professional (IRP). Operations were severely affected by liquidity distress, including an inventory write-down of ₹233.08 million due to unutilized working capital.
- Consolidated revenue from operations dropped to ₹695.61 million in FY26 from ₹1,162.69 million in FY25
- Consolidated net loss widened significantly to ₹1,764.73 million for FY26 compared to ₹319.61 million in FY25
- Company admitted to CIRP by NCLT on April 15, 2026, suspending board powers under an IRP
- Inventory write-down of ₹233.08 million recognized due to working capital constraints causing batch rejections and expiry
- Facing CBI investigation initiated by lender SBI (currently stayed by Telangana High Court)
Vivimed Labs Limited has provided pre-facto intimation regarding the 8th meeting of its Committee of Creditors (CoC), scheduled for September 29, 2026, via audio-visual means. The company is currently undergoing Corporate Insolvency Resolution Process (CIRP) pursuant to an NCLT order dated April 15, 2026. The meeting is being convened by the Interim Resolution Professional, Narayana Swamy, under the Insolvency and Bankruptcy Code (IBC). In context, the company had previously defaulted on INR 376.43 Cr of bank facilities, impairing operations and working capital.
- 8th meeting of the Committee of Creditors (CoC) scheduled for Tuesday, September 29, 2026
- Company is under Corporate Insolvency Resolution Process (CIRP) initiated by NCLT order dated April 15, 2026
- Meeting conducted via Audio-Visual Means under Regulation 19 of IBBI Regulations, 2016
- Financial context highlights an ongoing default on INR 376.43 Cr of bank facilities
Vivimed Labs Limited has announced that the 7th meeting of its Committee of Creditors (CoC) is scheduled for September 10, 2026, via audio-visual means. The company is currently undergoing a Corporate Insolvency Resolution Process (CIRP) pursuant to an NCLT order dated April 15, 2026. The meeting will be conducted under Regulation 19 of the IBBI CIRP Regulations by the Interim Resolution Professional. Company context reveals an ongoing default of ₹376.43 crore in bank facilities, which previously depressed turnover by 24.15% in FY2025.
- 7th meeting of the Committee of Creditors scheduled for September 10, 2026
- Company is under CIRP following NCLT order dated April 15, 2026
- Meeting conducted via audio-visual means under Regulation 19 of IBBI CIRP Regulations
- Interim Resolution Professional registration valid until June 30, 2027
Vivimed Labs Limited has submitted a pre-facto intimation for the 6th meeting of its Committee of Creditors (CoC), scheduled for August 18, 2026, via audio-visual means. The company was admitted into the Corporate Insolvency Resolution Process (CIRP) under an NCLT order dated April 15, 2026. Previous CoC meetings were conducted on June 18, July 4, July 11, and July 20, 2026. The resolution proceedings follow substantial financial distress and defaults on ₹376.43 Cr of bank facilities.
- 6th Committee of Creditors (CoC) meeting scheduled for August 18, 2026
- Company is under Corporate Insolvency Resolution Process via NCLT order dated April 15, 2026
- Previous CoC meetings held on June 18, 2026 (3rd), July 4, 2026 (4th), and July 20, 2026 (5th)
- Insolvency addresses ongoing default on ₹376.43 Cr bank facilities
Vivimed Labs has submitted a monthly status report from its Registrar and Share Transfer Agent (RTA), Aarthi Consultants Pvt Ltd, regarding the re-lodgement of physical share transfer requests. For the month of June 2026, the company reported zero (NIL) requests received, processed, or approved under the special SEBI window. This filing is a mandatory procedural requirement following a SEBI circular dated January 30, 2026. Investors should note that this administrative update does not address the company's ongoing financial distress, including a ₹376.43 Cr bank facility default.
- Reported NIL requests for re-lodgement of physical share transfers during June 2026.
- Compliance follows SEBI Circular dated January 30, 2026, regarding physical share transfers.
- The RTA report confirms zero requests were processed, approved, or rejected in the reporting period.
- Company remains under significant financial pressure with a reported ₹376.43 Cr default on bank facilities.
- FY2025 turnover declined by 24.15% due to restricted access to working capital.
Vivimed Labs has submitted copies of newspaper advertisements regarding its financial results for the quarter and year ended March 31, 2026. The advertisements were published in 'Financial Express' and 'Hosadigantha' on July 19, 2026, as per SEBI regulations. This is a procedural filing and does not contain the detailed financial statements themselves. Investors should note the company's existing financial distress, including a default of INR 376.43 Cr on bank facilities.
- Financial results pertain to the quarter and year ended March 31, 2026
- Advertisements were published in two newspapers on July 19, 2026
- Filing is compliant with SEBI Listing Obligations and Disclosure Requirements (Regulations 30 and 47)
- Company continues to manage a significant debt default of INR 376.43 Cr as per latest context
Vivimed Labs Limited has submitted its quarterly compliance certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018. The certificate, issued by Aarthi Consultants Private Limited, confirms that all dematerialization requests received between April 1, 2026, and June 30, 2026, were processed within the mandated 15-day timeframe. This process involves the cancellation of physical share certificates and updating depository records to reflect electronic ownership. This is a standard administrative filing required for all listed companies and has no impact on business operations.
- Compliance certificate covers the quarterly period from 01/04/2026 to 30/06/2026
- Dematerialization requests were processed within 15 days of receipt of security certificates
- Registrar and Share Transfer Agent (RTA) is Aarthi Consultants Private Limited (SEBI Regn. No. INR000000379)
- Physical certificates were mutilated and cancelled as per regulatory requirements
Vivimed Labs Limited has announced the closure of its trading window for all designated persons and their immediate relatives starting July 1, 2026. This action is a standard regulatory requirement under SEBI (Prohibition of Insider Trading) Regulations, 2015, preceding the announcement of financial results. The closure pertains to the quarter ended June 30, 2026. The window will remain shut until 48 hours after the financial results are officially declared and made public.
- Trading window closure begins on July 1, 2026
- Closure is in relation to financial results for the quarter ended June 30, 2026
- Window to reopen 48 hours after the results are declared to the exchanges
- Board meeting date for result approval to be announced in due course
Vivimed Labs has responded to NSE's clarification request regarding procedural lapses in its FY25 financial result filings. The company admitted to a filing delay, submitting results on May 31, 2025, at 12:13 PM despite the board meeting concluding at 22:10 PM the previous night, citing technical scanner issues. Furthermore, the company addressed a missing MD signature on the Statement on Impact of audit qualifications and reported ongoing errors in submitting revised XBRL data. These administrative and compliance hurdles, combined with the mention of audit qualifications, signal potential internal control weaknesses.
- Filing delay occurred for FY25 results, with submission happening over 14 hours after the board meeting concluded on May 30, 2025.
- The Statement on Impact of audit qualifications was signed by a Whole Time Director instead of the MD, who was absent from the meeting.
- Discrepancies were identified in XBRL filings, and the company is currently facing technical errors while attempting to upload revised data.
- The company cited 'scanner problems' and 'technical issues' as the primary reasons for the regulatory non-compliance regarding filing timelines.
Vivimed Labs Limited is currently undergoing the Corporate Insolvency Resolution Process (CIRP) and has officially invited Expressions of Interest (EOI) from potential bidders. The company's financial health has deteriorated, with revenue falling from ₹136.80 Cr in FY24 to ₹103.60 Cr in FY25, and further down to ₹48.23 Cr for the first nine months of the current fiscal year. The resolution process aims to find a buyer or investor, with the final submission of resolution plans scheduled for August 28, 2026.
- Form G published inviting Expressions of Interest (EOI) with a submission deadline of June 29, 2026.
- Revenue from operations declined to ₹48.23 Cr for the nine-month period ended December 31, 2025.
- The company operates five manufacturing units, though the Bidar, Karnataka facility is currently non-operational.
- Total employee and workmen count stands at 352 as per the suspended board of directors.
- Final resolution plans from prospective applicants are expected to be submitted by August 28, 2026.
Vivimed Labs Limited has officially postponed its Board Meeting that was originally scheduled for May 30, 2026. The meeting was intended to approve the audited financial results for the quarter and full year ended March 31, 2026. The company has not yet provided a revised date, stating it will be intimated in due course. As a result, the trading window for designated persons will remain closed until 48 hours after the results are eventually declared.
- Board Meeting scheduled for May 30, 2026, for FY 2025-26 results approval is postponed.
- The postponement affects the reporting of both the final quarter and the full financial year results.
- A revised date for the meeting has not been determined yet.
- Trading window for company securities remains closed for designated persons until 48 hours post-declaration.
Vivimed Labs has submitted its Annual Secretarial Compliance Report for the financial year ended March 31, 2026. The report reveals a regulatory lapse where the company was fined a total of ₹2.95 lakh by BSE and NSE for delaying its December 2025 quarterly financial results by 25 days. Management attributed this delay to the resignation of the Chief Financial Officer (CFO) in February 2026. Aside from this specific instance, the secretarial auditor confirmed that the company generally complied with SEBI regulations and maintained proper board processes.
- Total penalty of ₹2.95 lakh (including GST) imposed by stock exchanges for non-compliance with Regulation 33.
- Financial results for the December 2025 quarter were submitted with a 25-day delay.
- Management cited the resignation of the CFO on February 6, 2026, as the reason for the filing delay.
- Secretarial auditor confirmed compliance with Secretarial Standards and SEBI Insider Trading regulations.
- No directors were found disqualified under Section 164 of the Companies Act, 2013.
The National Company Law Tribunal (NCLT), Bengaluru Bench, has initiated the Corporate Insolvency Resolution Process (CIRP) for Vivimed Labs Limited effective April 15, 2026. T Narayana Swamy has been appointed as the Interim Resolution Professional (IRP) to manage the company's affairs and oversee the debt resolution. Creditors are required to submit their claims by May 1, 2026, with the entire resolution process estimated to conclude by October 11, 2026. This development signals severe financial distress and poses a high risk of equity dilution or total loss for shareholders.
- NCLT Bengaluru Bench ordered the commencement of CIRP on April 15, 2026.
- T Narayana Swamy appointed as Interim Resolution Professional (IRP) with registration number IBBI/IPA-002/IP-N01078/2020-2021/13427.
- Last date for creditors to submit claims with proof is May 1, 2026.
- Estimated date of closure for the insolvency resolution process is October 11, 2026.
- The company's management is now vested with the IRP under the provisions of the Insolvency and Bankruptcy Code (IBC).
The National Company Law Tribunal (NCLT) Bengaluru Bench has admitted Vivimed Labs Limited into the Corporate Insolvency Resolution Process (CIRP) on April 15, 2026. The petition was filed by operational creditor Blue Cube Germany Assets GmbH & Co. KG for a default amounting to approximately ₹2.78 crore, including interest. Despite a 2019 civil court decree and subsequent payment undertakings in 2021, the company failed to discharge its liabilities. An Interim Resolution Professional (IRP) has been appointed to manage the company's operations and seek a resolution plan.
- NCLT Bengaluru admitted the company to CIRP under Section 9 of the IBC following a default on operational debt.
- The default stems from a 2012 supply agreement with a total claim of ₹2.78 crore as per the demand notice.
- The company failed to honor a 2019 court decree and subsequent payment memos filed in 2021.
- The tribunal noted multiple other insolvency petitions are pending against the company, indicating widespread financial stress.
- An Interim Resolution Professional (IRP) has been appointed, and the next hearing is scheduled for June 24, 2026.
Vivimed Labs Limited has filed its quarterly compliance certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations for the quarter ended March 31, 2026. The company's Registrar and Share Transfer Agent, Aarthi Consultants Private Limited, confirmed that all security certificates received for dematerialization were processed within the mandated 15-day window. The process involved mutilating and cancelling physical certificates and updating the depository as the registered owner in the company's records. This is a standard procedural filing required for all listed entities in India.
- Compliance certificate issued for the quarter ending March 31, 2026.
- Dematerialization of securities completed within the mandatory 15-day window.
- RTA Aarthi Consultants Private Limited confirmed cancellation of physical certificates.
- Depository names substituted in records for all processed demat requests.
Financial Performance
Revenue Growth by Segment
Consolidated revenue declined by 24.15% YoY to INR 120.64 Cr in FY2025. Standalone revenue, primarily driven by domestic pharma and chemicals, fell 26.36% to INR 107.79 Cr. Historically, the API segment accounted for 50% of revenue, while Finished Dosage Formulations (FDF) contributed 38%.
Geographic Revenue Split
The company maintains a global footprint with 12 manufacturing facilities and 6 R&D centers across India, China, Europe, and the US. Historically, overseas operations in Spain and Mexico accounted for approximately 50% of overall revenue.
Profitability Margins
Net Profit Margin remained negative at -26.49% in FY2025, though it showed a slight improvement from -28.57% in FY2024. Standalone net margins were lower at -29.22% due to higher operational deleverage on the domestic manufacturing base.
EBITDA Margin
Consolidated EBITDA margin improved to -7.19% (INR -8.68 Cr) in FY2025 from -14.74% (INR -23.45 Cr) in FY2024. This improvement was driven by a reduction in operating losses despite the 24.15% drop in total income.
Capital Expenditure
Planned capital expenditure is not disclosed for the upcoming period; however, the company recorded depreciation and amortization of INR 20.22 Cr in FY2025, reflecting a significant historical investment in its 12 global manufacturing units.
Credit Rating & Borrowing
The company is rated 'CARE D; ISSUER NOT COOPERATING', indicating a 100% default status on its bank facilities. Total rated debt stands at INR 376.43 Cr, comprising INR 266.93 Cr in long-term and INR 109.50 Cr in short-term facilities.
Operational Drivers
Raw Materials
Key raw materials include chemical intermediates for API synthesis and specialty chemicals such as photochromic dyes and anti-microbials, which collectively represent the bulk of the direct manufacturing cost.
Import Sources
Raw materials are sourced globally to support facilities in India, China, Europe, and the US. Specific sourcing countries for FY2025 are not disclosed in available documents.
Capacity Expansion
Current infrastructure includes 12 manufacturing facilities and 6 R&D centers. No specific expansion plans were detailed for FY2026 due to current liquidity constraints and debt default status.
Raw Material Costs
Raw material costs are a primary driver of the negative EBITDA; however, specific cost as a percentage of revenue for FY2025 was not explicitly broken down in the summary financials.
Manufacturing Efficiency
Manufacturing efficiency is severely impacted by cash flow mismatches, leading to ongoing delays in debt servicing and likely underutilization of the 12 global facilities.
Strategic Growth
Growth Strategy
The company aims to leverage the growing global demand for generics and opportunities arising from patent expiries in developed markets. The strategy involves utilizing USFDA-approved units in Spain and Mexico to supply high-value APIs and formulations to marquee global clients.
Products & Services
Active Pharmaceutical Ingredients (APIs), Finished Dosage Formulations (FDF), Hair Dyes, Photochromic Dyes, Anti-Microbials, and Imaging Chemicals.
Brand Portfolio
Vivimed, Uquifa (Spain), Soneas (Hungary).
Market Expansion
The company targets developed markets through its global support offices in India, China, Europe, and the US, focusing on generic drug opportunities.
Market Share & Ranking
Vivimed is a world leader in the development of innovative photochromic dyes.
Strategic Alliances
Maintains contract manufacturing relationships with marquee clients including Novartis, Glenmark, Lupin, GSK, Dr. Reddy’s, Cipla, Abbott, and Merck Serono.
External Factors
Industry Trends
The pharmaceutical industry is seeing increased spending on medicines, expected to reach $1.4 Trillion globally, with a shift toward branded medicines in developed markets and high-volume generics in emerging markets.
Competitive Landscape
Competes with global API and specialty chemical manufacturers; competitive positioning is currently weakened by a 'CARE D' credit rating and issuer non-cooperation.
Competitive Moat
The company's moat is built on its 12 global manufacturing facilities and 6 R&D centers, particularly its USFDA-approved units and patented photochromic dye technology, though sustainability is threatened by current liquidity defaults.
Macro Economic Sensitivity
Highly sensitive to global healthcare spending and regulatory changes in the US and Europe, which are primary markets for its USFDA-approved facilities.
Consumer Behavior
Increased global demand for affordable healthcare is driving the shift toward generic formulations, which aligns with Vivimed's FDF business segment.
Geopolitical Risks
Operations in Spain, Mexico, Hungary, China, and the USA expose the company to trade barriers and regulatory shifts in multiple jurisdictions.
Regulatory & Governance
Industry Regulations
Operations are subject to stringent USFDA standards for Spanish and Mexican plants, as well as local manufacturing standards in India and China. Compliance is critical for maintaining the 88% revenue contribution from the Pharma segment.
Taxation Policy Impact
The company recorded a tax benefit of INR 0.11 Cr on a consolidated basis in FY2025 due to reported losses.
Legal Contingencies
The company faces a significant audit qualification regarding the non-recognition of interest expense amounting to INR 57.44 Cr for FY2025, which materially misstates the reported net loss and total liabilities.
Risk Analysis
Key Uncertainties
The primary uncertainty is the company's ability to continue as a 'going concern' given the 'CARE D' rating and the fact that total liabilities (INR 956.00 Cr) exceed total assets (INR 920.83 Cr) on a consolidated basis.
Geographic Concentration Risk
Significant geographic concentration in India and Europe (Spain/Hungary), with international subsidiaries being critical for 50% of historical revenue.
Third Party Dependencies
High dependency on lenders for working capital; the 'Issuer Not Cooperating' status suggests a breakdown in relationship with credit providers.
Technology Obsolescence Risk
Risk is mitigated by 6 R&D centers and patented processes in the specialty chemicals division, particularly in photochromic dyes.
Credit & Counterparty Risk
Credit exposure is high; the company's own default status likely limits its ability to secure favorable credit terms from suppliers, further straining the 24.15% declining revenue base.
